Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of savolitinib versus paclitaxel in MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma after first-line treatment failure
CTR20261803Phase 3Active
- Sponsor
- HUTCHMED
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib, paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by HUTCHMED. Started May 2026; status: active.
02
Drugs
savolitinibpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20261803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261803.